A transfer of blood cells between the fetal and maternal circulations has been observed, despite the physical separation of both systems by villous trophoblast layers of the placenta. Passage of fetal cells into the maternal circulation is a well-known phenomenon. There are several lines of evidence that suggest that fetal cells can persist for decades post partum. 1 Persistent fetal cells can be involved in the pathogenesis of connective tissue disease. 2, 3 It has been more than 3 decades since transmission of intact maternal cells to the fetus was first described. [4] [5] [6] Leakage of maternal cells into the fetal circulation occurs during the second and third trimester, but the exact function of this transfer is unknown. Socie et al 7 estimated that up to 6% of the cells in umbilical cord blood could be maternal in origin. These findings raise concern as to whether umbilical cord blood is suitable as an alternate source of hematopoietic stem cells for clinical transplantation. Recently maternal deoxyribonucleic acid (DNA) was detected in umbilical cord blood by using polymerase chain reaction (PCR) amplification of minisatellite sequences. The presence of maternal DNA was demonstrated in 1% to 100% of umbilical cord blood samples. 8, 9 The objective of this study was to determine the frequency of cord blood contamination by maternal genetic material. We used fluorescent PCR amplification of highly polymorphic short tandem repeat markers (STRs) to detect maternal DNA in umbilical cord plasma collected several minutes after delivery. Because contaminating maternal DNA may be enriched in cord plasma, 10 cord plasma was used as a source of maternal DNA. Therefore, the use of plasma may potentially enhance the sensitivity for the detection of maternal DNA in umbilical cord samples.
up to 6% of the cells in umbilical cord blood could be maternal in origin. These findings raise concern as to whether umbilical cord blood is suitable as an alternate source of hematopoietic stem cells for clinical transplantation. Recently maternal deoxyribonucleic acid (DNA) was detected in umbilical cord blood by using polymerase chain reaction (PCR) amplification of minisatellite sequences. The presence of maternal DNA was demonstrated in 1% to 100% of umbilical cord blood samples. 8, 9 The objective of this study was to determine the frequency of cord blood contamination by maternal genetic material. We used fluorescent PCR amplification of highly polymorphic short tandem repeat markers (STRs) to detect maternal DNA in umbilical cord plasma collected several minutes after delivery. Because contaminating maternal DNA may be enriched in cord plasma, 10 cord plasma was used as a source of maternal DNA. Therefore, the use of plasma may potentially enhance the sensitivity for the detection of maternal DNA in umbilical cord samples.
Material and methods
Pregnant laboring women at term (n = 57) with normal pregnancies were recruited. Several minutes after delivery, cord blood samples were collected by gravity into glass tubes containing ethylenediamine tetraacetic acid (EDTA), without any attempt to flush the umbilical vessels. To avoid contamination with maternal blood the umbilical cord was cleaned carefully with saline. Maternal blood samples were obtained at the same time. The gestational ages of all pregnancies were at least 37 weeks and all women delivered spontaneously.
Preparation of samples and DNA extraction. The procedures of DNA extraction and PCR amplification using STRs have been described previously. 11, 12 Umbilical blood samples were centrifuged at 2000g, and plasma was removed from the collection tubes and transferred into plain polypropylene tubes. The plasma samples were recentrifuged at 3000g and the supernatants were stored in fresh tubes at -20°C. Deoxyribonucleic acid was extracted from plasma samples by using a QIAamp Blood kit (Qiagen, Valencia, Calif). Plasma samples of 1 mL per column were used for DNA extraction, and DNA was eluted with 50 µL of buffer. Extraction of DNA from whole blood samples obtained from the mother was performed by using the same QIAamp Blood Kit. Maternal whole blood samples of 200 µL were used per column for DNA extraction.
Polymerase chain reaction. Highly polymorphic STRs were chosen for detection of maternal DNA. D21S11, D21S1411, and D21S1412 are present on chromosome 21; D18S386, D18S535, and DNA sequences from the myelin basic protein (MBP) gene are located on chromosome 18; D13S631 and D13S634 are specific for chromosome 13. The primers for the repeats of the MBP gene amplify two STR loci (locus A and locus B) simultaneously. Three sets of STR markers were used as described by Pertl et al. 13 The forward oligonucleotide primers for D21S11, D21S1412, D13S634, MBP-A, MBP-B, D18S386, D18S535 were 5' end-labeled with 5-carboxy-fluorescein (blue), whereas the forward primers D21S1411 and D13S631 were labeled with 2', 7'-di-methyloxy 4', 5'-dichloro 6 carboxy-fluorescein (green).
Polymerase chain reaction amplification was performed in a total volume of 25 µL containing extracted genomic DNA (5 µL), 200 µM deoxynucleotide triphosphates 5-20 pmoles of each primer, 1X Taq polymerase buffer (3 mmol/L MgCl 2 ), and 1.5 U Taq polymerase (both Promega, Madison, Wis). After initial denaturation at 94°C for 5 minutes, hot start PCR was done for 30-33 cycles (plasma samples) or for 20 cycles (whole blood) at 94°C for 48 s, 60°C for 48 s, and 72°C for 1 min. Final extension was at 72°C for 5 min. The PCR products (3 µL) were mixed with 2.6 µL gel loading buffer and 0.4 µL Genescan-500 ROX (Applied Biosystems Inc, Warrington, UK) containing the reference molecular-size standard. Electrophoresis was performed on a 373 DNA sequencer (Applied Biosystems Inc) by using a 6% denaturating polyacrylamide gel.
The amplification products were analyzed and their relative fluorescent intensities were calculated by using Genescan 672 software (Applied Biosystems Inc). [11] [12] [13] Dilution experiments were performed to determine the sensitivity of the fluorescent PCR assay. Male DNA was diluted in female DNA (50%, 25%, 10%, 5%, 2.5%, 1%, 0.5%, 0.1%, 0.05%, 0.01%), leading to an allele specific detection sensitivity of 1% overall (range, 0.01% to 2.5%). 
Results
Fifty-seven mother-child pairs were studied. All mother/ child pairs analyzed were informative in at least 2 of 9 STR markers (mean, 5). Maternal specific alleles were amplified in 49 of 57 cord blood plasma samples and were found in 1 to 7 of 9 markers used ( Figure) . Maternal DNA was considered to be present when maternal specific alleles of at least two informative markers were amplified. In 6 mother-child pairs, only 1 maternal specific allele was amplified. By using this cut-off, we found maternal DNA in 43 of 57 cord plasma samples (75%), and 58% of all cord plasma samples (n = 33) had maternal alleles amplified in >50% of the informative markers. The most informative markers were D21S1411 (46/57 cases), D18S386 (44/57), and D21S1412 (43/57). The most sensitive markers were D21S1411 (26/57), MBP-B (25/57), and D18S535 (24/57). Maternal alleles were amplified in 25 of 33 informative pairs using MPB-B and in 24 of 30 pairs using D18S535. In contrast to these sensitive markers, amplified maternal alleles were detectable in only 8 of 32 informative pairs by using D13S634 (Table) .
Comment
Cord blood, which is typically discarded after delivery, is a source of transplantable stem and progenitor cells. 14 For this reason, long-term storage of umbilical cord blood has been initiated. Myeloablative treatment, followed by hematopoietic reconstruction with stem cells from umbilical cord blood, can cure children with leukemia. 15 The initial clinical results of related and unrelated pediatric bone marrow replacements that use umbilical cord blood-derived stem cells have been encouraging. However, the increasing body of knowledge that has appeared in the literature over the past 6 years suggests that a reassessment of the risk of maternal cell contamination of this material is indicated.
Both maternal cells and DNA are present in umbilical cord blood samples, which contain a cellular and a plasma component. Initial studies focused on the detection of cells by using fluorescent in situ hybridization (FISH) techniques.
Hall et al 16 screened 49 male cord blood samples for maternal cells by using probes for the X and Y chromosomes. Maternal cells were found in 10 of 49 (20%) cord blood samples obtained from male newborns. The use of FISH had a detection sensitivity of 0.1%. However, this method was hampered by the practical difficulties associated with the visual screening of 1000 nuclei per case. Furthermore, the main limitation of this technique was that it was only applicable when the newborn was male.
The presence of maternal DNA sequences has been documented in whole blood umbilical cord samples. Socie et al 7 used PCR amplification of 2 minisatellite regions to detect maternal alleles in umbilical cord samples (n = 47). Maternal specific alleles were detected in 1 of 42 cord blood samples (2%) that were informative for the markers used. Similarly, in a more recent study, Briz et al 8 assessed maternal cellular cord blood contamination by using PCR analysis of 6 minisatellite regions. In their study, 79 of 80 mother-child pairs were informative. However, maternal DNA was found in only 1.26% of the cord blood samples. Petit et al 9 used PCR amplification of the human thyroid peroxidase gene to screen for maternal cell contamination. Out of 47 umbilical cord blood samples only 10 were found to be informative. The informative mother-child pairs revealed the presence of uniquely maternal alleles in 100% of cases. In a subsequent study, this group investigated fetal blood samples that were collected at different gestational ages (from 20 to 35 weeks). 17 Twenty mother-child pairs were screened and 9 pairs were informative according to the thyroid peroxidase method. Maternal cells were detected in 8 of 9 fetal blood samples, but only during the third trimester of pregnancy. Lo et al 18 used 3 different PCR methods for the detection of maternal cells in fetal blood. The first system was based on the highly polymorphic region of the δ-and β-globulin genes, the second on the glutathione-Stransferase M1 locus, and the third on the polymorphisms at the locus of the angiotensin converting enzyme gene. Of 66 mother-baby pairs, 38 were informative using all 3 systems. Maternal specific alleles were detected in 16 informative cases (46%). Scaradavou et al 19 tested 213 umbilical cord blood samples for the presence of noninherited maternal human leukocyte antigen (HLA) genes by locus-specific PCR amplification. Maternal gene sequences were found in 38% of all samples.
Thus, when we concentrate on only the DNA obtained from maternal cells in umbilical cord blood samples, the range of published results extends from 1.2 to 100% of informative cases. Different methods of PCR and different gene sequences were amplified in these studies, and these differences might account for the wide variation in the results.
More recently, the presence of maternal cell-free DNA in umbilical cord plasma samples has been described. Lo et al 20 compared the percent transfer of maternal nucleated cells and plasma DNA by using real time PCR. In this study the informativeness of mother-baby pairs was 32%. Maternal DNA sequences were present in 30% of the informative cord plasma samples compared to 24% in the cellular fraction.
In the present study, we investigated 57 mother-child pairs for the presence of maternal DNA sequences in umbilical cord plasma samples. Polymerase chain reaction amplification of 9 highly polymorphic short tandem repeats was used to detect maternal-specific alleles in umbilical cord plasma samples. All samples were informative in at least 2 to 7 different STR markers. Because it is sometimes difficult to distinguish between stutter bands and amplified maternal alleles, we used a cut-off of a minimum of two amplified maternal alleles to prove the presence of maternal DNA in cord plasma. By using this cut-off, we found maternal DNA sequences in 75% of cord plasma samples. Although we did not use real-time PCR, our method still demonstrates a high level of sensitivity of detection of maternal sequences.
In summary, all of the available studies seem to indicate that both maternal cells and free DNA are present in umbilical cord blood samples. The method described here might be a useful new technique for screening umbilical cord blood samples for the presence of maternal DNA sequences. The actual source of maternal DNA in the umbilical cord plasma is unknown at present. It can be speculated that some of the cell-free maternal DNA in the plasma is derived from maternal blood cells undergoing apoptosis. Further studies are needed to assess whether such contamination by maternal cells or maternal DNA would have a negative effect on the use of harvested cord blood for transplantation purposes. It should be kept in mind that the biologic significance of the trafficking of maternal DNA into the fetal circulation still remains to be elucidated, and animal models are being developed for this purpose. Recent data in the mouse suggest two independent pathways of maternal cell transmission to offspring: transplacentally during gestation and via breast milk after birth. 21 In addition, preliminary FISH data from our laboratory indicate that maternal cells are capable of migrating from the peripheral circulation into newborn tissues. 22 
